Regular versus poor antidepressant use tied to lower risk for advanced diabetic complications, mortality in patients with depression and diabetes
Polygenic variants tied to similar risk for developing glaucoma as some monogenic variants and are more prevalent in the general population
Findings seen in double-blind, randomized, placebo-controlled discontinuation trial that was stopped early for efficacy
Antidepressant therapy more effective than supervised physical activity at three and six months
Contrast sensitivity impairment may affect cognitive decline across more domains than other vision measures
Risk for death significantly reduced with prior statin and/or antihypertensive use among those with history of CVD and/or hypertension
Prespecified analysis of RCT shows reduced risk with dapagliflozin versus placebo for composite outcome that included kidney, CV events
Increased risks seen for survivors of leukemia, lymphoma, multiple myeloma, skin cancer, and lung cancer in subgroup analyses
Multivariable-adjusted hazard ratios for all-cause mortality reduced for one to 59, 60 to 149, 150 to 299, and ≥300 minutes/week
No evidence of effect modification seen in interaction analyses using polygenic score with seven polymorphisms, CYP1A2 rs762551 alone
Please login or register first to view this content.
Login Register